TopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Hexachlorophene

CAS 70-30-4

Hexachlorophene (CAS 70-30-4) is a Phase 4 pharmaceutical compound with 38 bioactivity targets and 22 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
45
SOURCE DrugCentral
Adverse signals
22
SOURCE IUPHAR/BPS
PubMed IDs
1
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Hexachlorophene
CAS Number
70-30-4
UNII
IWW5FV6NK2
InChIKey
ACGUYXCXAPNIKK-UHFFFAOYSA-N
ChEMBL ID
CHEMBL496
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural producttherapeutic flagtopicalwithdrawn flag
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL496 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

SOURCE EMBL-EBI ChEMBL 45 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- Potency 22265.248815165876 nM 154 -
- IC50 10775.842093023257 nM 85 -
- AC50 13373.530769230769 nM 39 -
- EC50 13398.07142857143 nM 14 -
- MIC 0.45249999999999996 ug.mL-1 12 -
- Ki 2293.46 nM 10 -
- MIC 8135 nM 8 -
Acetylcholinesterase
Enzyme
IC50 5.521 - Homo sapiens
Sodium/potassium-transporting ATPase subunit alpha-2
Ion channel
IC50 5.212 - Sus scrofa
Prostaglandin G/H synthase 2
Enzyme
IC50 6.191 - Homo sapiens
Adenosine receptor A2a
GPCR
Ki 6.043 - Homo sapiens
Alpha-2A adrenergic receptor
GPCR
Ki 5.686 - Homo sapiens
Sodium-dependent serotonin transporter
Transporter
Ki 5.636 - Homo sapiens
5-hydroxytryptamine receptor 2B
GPCR
Ki 5.441 - Homo sapiens
5-hydroxytryptamine receptor 2C
GPCR
Ki 5.618 - Homo sapiens
Alpha-2C adrenergic receptor
GPCR
Ki 5.994 - Homo sapiens
Adenosine receptor A3
GPCR
Ki 6.442 - Homo sapiens
Estrogen receptor
Nuclear hormone receptor
IC50 5.67 - Homo sapiens
Estrogen receptor beta
Nuclear hormone receptor
IC50 7.01 - Homo sapiens
Cytochrome P450 1A2
Enzyme
IC50 5.882 - Homo sapiens
Epidermal growth factor receptor
Kinase
IC50 6.126 - Homo sapiens
Cytochrome P450 2C19
Enzyme
IC50 5.911 - Homo sapiens
D-lactate dehydrogenase
Enzyme
- - - Escherichia coli (strain K12)
Tyrosine-protein kinase Lck
Kinase
IC50 5.614 - Homo sapiens
Tyrosine-protein kinase Fyn
Kinase
IC50 5.459 - Homo sapiens
Receptor tyrosine-protein kinase erbB-2
Kinase
IC50 5.479 - Homo sapiens
Thromboxane-A synthase
Enzyme
IC50 5.51 - Homo sapiens
Mitogen-activated protein kinase 3
Kinase
IC50 5.605 - Homo sapiens
Mitogen-activated protein kinase 14
Kinase
IC50 7.057 - Homo sapiens
Substance-K receptor
GPCR
Ki 5.86 - Homo sapiens
Androgen receptor
Transcription factor
Ki 5.479 - Rattus norvegicus
Mitogen-activated protein kinase 1
Kinase
IC50 6.708 - Homo sapiens
Enoyl-[acyl-carrier-protein] reductase [NADH] FabI
Enzyme
INHIBITOR - - Escherichia coli (strain K12)
Zinc finger protein mex-5
Cytosolic other
EC50 4.72 - Caenorhabditis elegans
Transitional endoplasmic reticulum ATPase
Enzyme
IC50 5.26 - Homo sapiens
Heat shock cognate 71 kDa protein
Unclassified
IC50 4.56 - Homo sapiens
Heat shock 70 kDa protein 1A
Unclassified
IC50 4.72 - Homo sapiens
M1-family alanyl aminopeptidase
Enzyme
IC50 4.24 - Plasmodium falciparum (isolate 3D7)
Cytoplasmic zinc-finger protein
Unclassified
EC50 4.34 - Caenorhabditis elegans
Envelope glycoprotein gp160
Viral envelope protein
IC50 5.14 - Human immunodeficiency virus 1
Macrophage migration inhibitory factor
Unclassified
Ki 5.26 - Homo sapiens
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D
Unclassified
IC50 5.01 - Homo sapiens
78 kDa glucose-regulated protein
Unclassified
IC50 5.04 - Homo sapiens
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120
Unclassified
IC50 5.14 - Human immunodeficiency virus 1
N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, N-acyl phosphatidylethanolamine phospholipase D, NAPE-PLD, NAPE-hydrolyzing phospholipase D, EC 3.1.4.54
Unclassified
IC50 4.96 - Mus musculus
SOURCE IUPHAR/BPS 1 interaction

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

TargetAction AffinityPubMed
N -Acylphosphatidylethanolamine-phospholipase D
NAPEPLD
Inhibition 5.010000228881836 pIC50 32284327
SOURCE NLM RxNorm 1 name row

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
hexachlorophene 5293 IN RXNORM
SOURCE SIDER 6 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Dermatitis hexachlorophene LLT C0011603
Dermatitis hexachlorophene PT C0011603
Erythema hexachlorophene PT C0041834
Photosensitivity hexachlorophene LLT C0349506
Photosensitivity reaction hexachlorophene PT C0162830
Redness hexachlorophene LLT C0332575
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Hexachlorophene used for in pharmaceutical contexts?

Hexachlorophene (CAS 70-30-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Hexachlorophene?

Hexachlorophene has 22 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Discomfort, Disturbance in attention, Dizziness, Drug ineffective, Drug ineffective for unapproved indication. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Hexachlorophene also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Hexachlorophene with EU status "restricted".

What clinical phase is Hexachlorophene in?

Hexachlorophene is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Hexachlorophene?

Hexachlorophene has 45 bioactivity rows in this page query. Rendered target entries include Acetylcholinesterase, Sodium/potassium-transporting ATPase subunit alpha-2, Prostaglandin G/H synthase 2, Adenosine receptor A2a, Alpha-2A adrenergic receptor.